Erythropoietin ameliorates genetamicin-induced renal toxicity: A biochemical and histopathological study

Journal of Nephropathology

Volumn 1, Issue 2, 2012, Pages 109-116

  Rafieian Kopaei, Mahmoud ^a   Nasri, Hamid ^b   Nematbakhsh, Mehdi ^b   Baradaran, Azar ^b   Gheissari, Alaleh ^c   Rouhi, Hamid ^a   Ahmadi Soleimani, Seyed Mohammad ^d   Baradaran Ghahfarokhi, Milad ^b   Ghaed Amini, Fatemeh ^a   Ardalan, Mohammadreza ^e  

^a SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Erythropoietin; Gentamicin; Tubular toxicity

Indexed keywords

EID: 84866751268     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.5812/nephropathol.7533     Document Type: Article

References (46)

1. Prokai A, Fekete A, Banki NF, Muller V, Ver A, Degrell P, et al. Renoprotective effect of erythropoietin in rats subjected to ischemia/reperfusion injury: gender differences. Surgery. 2011;150(1):39-47.
2. Heyman SN, Rosenberger C, Rosen S. Acute kidney injury: lessons from experimental models. Contrib Nephrol. 2011;169:286-96.
3. Khajehdehi P. Turmeric: Reemerging of a neglected Asian traditional remedy. Journal of Nephropathology. 2012;1(1).
4. Uz E, Uz B, Kaya A, Akdeniz D, BavbekRuzgaresen N, HilmiTurgut F, et al. Protective effect of erdosteine on cyclosporine induced chronic nephrotoxicity in rats. Nephro- Urology Monthly. 2011;3(04):280-4.
5. Rosen S, Stillman IE. Acute tubular necrosis is a syndrome of physiologic and pathologic dissociation. J Am Soc Nephrol. 2008;19(5):871-5.
6. Tayebi Khosroshahi H. Short history about renal transplantation program in Iran and the world: Special focus on world kidney day 2012. Journal of Nephropathology. 2012;1(1).
7. Tolou-Ghamari Z. Nephro and neurotoxicity, mechanisms of rejection: A review on Tacrolimus and Cyclosporin in organ transplantation. J Nephropathology. 2012;1(1):23-30.
8. Bernhardt WM, Eckardt KU. Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury. Curr Opin Crit Care. 2008;14(6):621-6.
9. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006;69(10):1806-13.
10. Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology (Carlton). 2006;11(4):306-12.
11. Provatopoulou ST, Ziroyiannis PN. Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. Hippokratia. 2011;15(2):109-15.
12. Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M. Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol. 2011;82(10):1291-303.
13. RezaTamadon M, Khatibinezhad A, Ghorbani R, Soleimani A, Malek F, Jalalzadeh M, et al. The impact of human recombinant erythropoietin on renal function in patients with chronic kidney disease. Nephro-Urology Monthly. 2011;3(02):114-6.
14. De Beuf A, D’Haese PC, Verhulst A. Epoetin delta as an antifibrotic agent in the remnant kidney rat: a possible role for transforming growth factor beta and hepatocyte growth factor. Nephron Exp Nephrol. 2010;115(3):e46-59.
15. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011;1(1):3.
16. Hariprasad G, Kumar M, Rani K, Kaur P, Srinivasan A. Aminoglycoside induced nephrotoxicity: molecular modeling studies of calreticulin-gentamicin complex. J Mol Model. 2012;18(6):2645-52.
17. Ali BH, Al Za’abi M, Blunden G, Nemmar A. Experimental gentamicin nephrotoxicity and agents that modify it: a mini-review of recent research. Basic Clin Pharmacol Toxicol. 2011;109(4):225-32.
18. Tavafi M, Ahmadvand H, Toolabi P. Inhibitory effect of olive leaf extract on gentamicin-induced nephrotoxicity in rats. Iran J Kidney Dis. 2012;6(1):25-32.
19. Tavafi M, Ahmadvand H. Effect of rosmarinic acid on inhibition of gentamicin induced nephrotoxicity in rats. Tissue Cell. 2011;43(6):392-7.
20. Kopple JD, Ding H, Letoha A, Ivanyi B, Qing DP, Dux L, et al. L-carnitine ameliorates gentamicin-induced renal injury in rats. Nephrol Dial Transplant. 2002;17(12):2122-31.
21. Juan SH, Chen CH, Hsu YH, Hou CC, Chen TH, Lin H, et al. Tetramethylpyrazine protects rat renal tubular cell apoptosis induced by gentamicin. Nephrol Dial Transplant. 2007;22(3):732-9.
22. Kadkhodaee M, Khastar H, Arab HA, Ghaznavi R, Zahmatkesh M, Mahdavi-Mazdeh M. Antioxidant vitamins preserve superoxide dismutase activities in gentamicin-in duced nephrotoxicity. Transplant Proc. 2007;39(4):864-5.
23. Ghaznavi R, Kadkhodaee M. Comparative effects of selective and non-selective nitric oxide synthase inhibition in gentamicin-induced rat nephrotoxicity. Arch Toxicol. 2007;81(6):453-7.
24. Kadkhodaee M, Khastar H, Faghihi M, Ghaznavi R, Zahmatkesh M. Effects of co-supplementation of vitamins E and C on gentamicin-induced nephrotoxicity in rat. Exp Physiol. 2005;90(4):571-6.
25. Derakhshanfar A, Bidadkosh A, Sadeghian M. L-methionine attenuates gentamicin nephrotoxicity in male Wistar rat: pathological and biochemical findings. Iranian Journal of Veterinary Research. 2009;10(4).
26. Lee DW, Kwak IS, Lee SB, Song SH, Seong EY, Yang BY, et al. Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat. J Korean Med Sci. 2009;24 Suppl:S170-5.
27. Jabbari M, Rostami Z, Jenabi A, Bahrami A, Mooraki A. Simvastatin ameliorates gentamicin-induced renal injury in rats. Saudi J Kidney Dis Transpl. 2011;22(6):1181-6.
28. Nasri H, Mortazavi M, Ghorbani A, Shahbazian H, Kheiri S, Baradaran A, et al. Oxford-MEST classification in IgA nephropathy patients: A report from Iran. Journal of Nephropathology. 2012;1(1):31-42.
29. Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, et al. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol. 2012;25(3):410-7.
30. ESHRAGHI JF, NEMATBAKHSH M, NASRI HAMID TA, HAGHIGHI M, PEZESHKI Z, SAFARI TAHEREH AF. The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS). 2011;16(11):1389-96.
31. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19(2):348-55.
32. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol. 1994;266(3 Pt 2):F360-6.
33. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 2001;16(5):932-8.
34. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17(12):1754-5.
35. Gong H, Wang W, Kwon TH, Jonassen T, Li C, Ring T, et al. EPO and alpha-MSH prevent ischemia/reperfusioninduced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int. 2004;66(2):683-95.
36. Dang J, Jia R, Tu Y, Xiao S, Ding G. Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother. 2010;64(10):681-5.
37. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol. 2007;376(1-2):1-43.
38. Ates E, Yalcin AU, Yilmaz S, Koken T, Tokyol C. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg. 2005;75(12):1100-5.
39. Rjiba-Touati K, Boussema IA, Belarbia A, Achour A, Bacha H. Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney. Int J Toxicol. 2011;30(5):510-7.
40. Rjiba-Touati K, Ayed-Boussema I, Bouaziz C, Belarbia A, Azzabi A, Achour A, et al. Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: antigenotoxic and antiapoptotic effect. Drug Chem Toxicol. 2012;35(1):89-95.
41. Wang W, Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol. 2008;588(2-3):135-40.
42. Goldfarb M, Rosenberger C, Ahuva S, Rosen S, Heyman SN. A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats. Ren Fail. 2006;28(4):345-50.
43. Ghaznavi R, Faghihi M, Kadkhodaee M, Shams S, Khastar H. Effects of nitric oxide on gentamicin toxicity in isolated perfused rat kidneys. J Nephrol. 2005;18(5):548-52.
44. Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet. 2004;19(3):159-70.
45. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009;30(3):253-60.
46. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int. 2010;77(11):1020-30.